Isah Ambrose O, Opadeyi Abimbola O, Tumwijukye Henry, Cobelens Frank, Smith Diede, Ndomondo-Sigonda Margareth, Harmark Linda, Tanui Paul, Tiemersma Edine, Mmbaga Blandina T, Mahlangu Gugu, Ayinbuomwan Stephen A, Soulaymani Rachida, Pandit Jayesh M
Department of Clinical Pharmacology and Therapeutics, School of Medicine, College of Medical Sciences, University of Benin/University of Benin Teaching Hospital, Benin City, Edo State PMB 1154, Nigeria.
Department of Clinical Pharmacology and Therapeutics, University of Benin/University of Benin Teaching Hospital, Benin City, Nigeria.
Ther Adv Drug Saf. 2023 Jul 24;14:20420986231188836. doi: 10.1177/20420986231188836. eCollection 2023.
An important factor hindering the growth of pharmacovigilance (PV) in resource-limited settings is the lack of adequate funds to establish a functional National Pharmacovigilance System. Consequently, the crucial function of monitoring and ensuring the availability of safe medicines in these settings cannot be guaranteed considering the peculiarities of diseases and medicines used.
The objective of this paper is to provide an overview as to the availability of potential sources of funds, which could be explored to ensure Medicine Safety and to proffer a potential framework likely to ensure sustainable funding of PV in Africa.
METHODS/PROCESSES: The process of developing this framework entailed a review of PV financing in some developed economies, a landscape study of funding of PV in some African countries, an in-depth understanding of the PV system and the organisational structure and nexus between the regulatory agencies and National Pharmacovigilance Centre. Critical points for consideration included the sources of funds, revenue pool, the disbursement of funds, budgeting and expenditure profile and the legal framework. Consultative meetings, webinars and interviews with experts were carried out.
The findings showed that most of the PV systems were mainly integrated into the regulatory agencies regarding operational and fiscal governance with few facilities being independent of the regulatory agencies. The main source of funding was from the government with significant donor funding which is ad hoc and non-sustainable. Several potential sources were identified but yet to be exploited. There were no legal provisions for PV financing. A framework likely to ensure sustainable PV financing is suggested to capture all available sources of funding, mine the potential sources providing a sizeable pool of revenue to address its activities and enabling legal framework which will engender autonomy. Furthermore, it will address the nexus between the regulatory agencies and the PV outfits, thus enabling appropriate share of resources and blockage of diversions.
In all, addressing the various elements identified in this study and providing the legal provisions which guarantees some degree of autonomy will provide a sustainable mechanism for PV funding in the resource-limited setting of Africa.
在资源有限的环境中,阻碍药物警戒(PV)发展的一个重要因素是缺乏足够资金来建立一个有效的国家药物警戒系统。因此,鉴于这些环境中所使用疾病和药物的特殊性,无法保证监测和确保安全药物供应这一关键功能的实现。
本文旨在概述可用于探索确保药物安全的潜在资金来源,并提出一个可能确保非洲药物警戒可持续资金的潜在框架。
方法/流程:制定该框架的过程包括对一些发达经济体的药物警戒融资情况进行审查,对一些非洲国家的药物警戒资金情况进行全面研究,深入了解药物警戒系统以及监管机构与国家药物警戒中心之间的组织结构和联系。需要考虑的关键点包括资金来源、收入池、资金支出、预算和支出概况以及法律框架。开展了协商会议、网络研讨会并与专家进行了访谈。
研究结果表明,大多数药物警戒系统在运营和财政管理方面主要整合到监管机构中,只有少数机构独立于监管机构。主要资金来源是政府,还有大量临时且不可持续的捐助资金。确定了几个潜在资金来源,但尚未加以利用。在药物警戒融资方面没有法律规定。建议建立一个可能确保药物警戒可持续融资的框架,以涵盖所有可用资金来源,挖掘潜在资金来源以提供可观的收入池来开展其活动,并建立一个能实现自主性的法律框架。此外,它将解决监管机构与药物警戒机构之间的联系,从而实现资源的合理分配并防止资金挪用。
总之,解决本研究中确定的各种要素并提供保证一定程度自主性的法律规定,将为非洲资源有限环境中的药物警戒资金提供一个可持续机制。